MCID: PPL018
MIFTS: 47

Papillary Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Papillary Adenocarcinoma

MalaCards integrated aliases for Papillary Adenocarcinoma:

Name: Papillary Adenocarcinoma 12 15 73
Infiltrating and Papillary Adenocarcinoma 12
Infiltrating Papillary Adenocarcinoma 12
Adenocarcinoma, Papillary 44
Adenocarcinoma Papillary 55

Classifications:



External Ids:

Disease Ontology 12 DOID:3112
MeSH 44 D000231
NCIt 50 C2853 C7438
SNOMED-CT 68 4797003 64524002

Summaries for Papillary Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which form complex papillary structures and exhibit compressive, destructive growth that replaces the normal tissue.

MalaCards based summary : Papillary Adenocarcinoma, also known as infiltrating and papillary adenocarcinoma, is related to aggressive digital papillary adenocarcinoma and gastric papillary adenocarcinoma. An important gene associated with Papillary Adenocarcinoma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Development EGFR signaling pathway and Cytoskeletal Signaling. The drugs Miconazole and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lung and cervix, and related phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and cellular

Wikipedia : 76 Papillary adenocarcinoma is a histological form of lung cancer that is diagnosed when the malignant... more...

Related Diseases for Papillary Adenocarcinoma

Diseases related to Papillary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 364)
# Related Disease Score Top Affiliating Genes
1 aggressive digital papillary adenocarcinoma 34.1 CEACAM5 MUC1
2 gastric papillary adenocarcinoma 34.0 ERBB2 TP53
3 eccrine papillary adenocarcinoma 33.8 KRT7 PGR
4 renal cell carcinoma, papillary, 1 32.4 ERBB2 KRT7 TP53
5 papillary serous adenocarcinoma 31.5 KRT7 NKX2-1 PGR TP53
6 adenocarcinoma 31.2 CDH1 ERBB2 MUC1 TP53
7 papillary adenoma 30.0 KRT7 NKX2-1 VIM
8 pulmonary sclerosing hemangioma 30.0 KRT7 NKX2-1
9 alveoli adenoma 30.0 KRT7 NKX2-1
10 duodenum adenocarcinoma 29.9 KRT7 MUC2
11 thymus adenocarcinoma 29.9 CEACAM5 KRT7
12 rete testis adenocarcinoma 29.9 CEACAM5 NKX2-1
13 squamous cell carcinoma 29.8 CDH1 ERBB2 MUC1 TP53
14 endometrial mucinous adenocarcinoma 29.7 MUC1 PGR VIM
15 pseudo-meigs syndrome 29.7 CDH1 MUC16
16 sclerosing hemangioma 29.6 KRT7 MUC1 NKX2-1 PGR
17 mucinous adenocarcinoma 29.5 KRT7 MUC1 MUC2 NKX2-1
18 cystadenoma 29.5 KRT7 MUC1 MUC2 PGR
19 cervical adenocarcinoma 29.4 ERBB2 KRT7 PGR TP53
20 sweat gland cancer 29.4 ERBB2 KRT7 PGR TP53
21 endometrial adenocarcinoma 29.4 ERBB2 KRT7 PGR TP53
22 transitional cell carcinoma 29.1 CDH1 ERBB2 KRT7 TP53
23 cholecystitis 29.1 CDH1 MUC1 MUC2 TP53
24 carcinosarcoma 29.1 ERBB2 KRT7 MUC1 PGR TP53 VIM
25 papillary carcinoma 28.9 CDH1 ERBB2 KRT7 MUC1 NKX2-1 PGR
26 gastric cancer 28.8 CDH1 CEACAM5 ERBB2 MUC2 TP53
27 cystadenocarcinoma 28.6 CEACAM5 ERBB2 KRT7 MUC1 MUC16 MUC2
28 ovarian cancer 28.3 CDH1 ERBB2 KRT7 MUC1 MUC16 MUC2
29 lung papillary adenocarcinoma 12.5
30 fallopian tube papillary adenocarcinoma 12.3
31 peritoneal serous papillary adenocarcinoma 12.3
32 papillary thymic adenocarcinoma 11.2
33 nasopharyngeal carcinoma 3 11.1
34 reticulum cell sarcoma 10.3 MUC1 VIM
35 melanotic neuroectodermal tumor 10.3 MUC1 VIM
36 syringoma 10.3 MUC1 VIM
37 ossifying fibromyxoid tumor 10.3 MUC1 VIM
38 mesenchymal chondrosarcoma 10.3 MUC1 VIM
39 perineurioma 10.3 MUC1 VIM
40 myxopapillary ependymoma 10.3 MUC1 VIM
41 syringocystadenoma papilliferum 10.3 MUC1 VIM
42 clear cell ependymoma 10.3 MUC1 VIM
43 adenomyoma 10.3 KRT7 MUC1
44 pleomorphic liposarcoma 10.3 MUC1 VIM
45 fibrous meningioma 10.3 MUC1 VIM
46 eccrine porocarcinoma 10.3 MUC1 VIM
47 chordoid meningioma 10.3 MUC1 VIM
48 middle ear adenoma 10.3 KRT7 MUC1
49 anaplastic ependymoma 10.3 MUC1 VIM
50 lipoadenoma 10.3 KRT7 MUC1

Graphical network of the top 20 diseases related to Papillary Adenocarcinoma:



Diseases related to Papillary Adenocarcinoma

Symptoms & Phenotypes for Papillary Adenocarcinoma

GenomeRNAi Phenotypes related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 8.92 ERBB2 MST1R MUC1 VIM

MGI Mouse Phenotypes related to Papillary Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.92 CDH1 ERBB2 KRT7 MUC2 NKX2-1 PGR
2 cardiovascular system MP:0005385 9.91 CDH1 ERBB2 MUC2 NKX2-1 PGR TP53
3 homeostasis/metabolism MP:0005376 9.81 CDH1 ERBB2 KRT7 MST1R MUC2 NKX2-1
4 endocrine/exocrine gland MP:0005379 9.8 CDH1 ERBB2 MST1R MUC2 NKX2-1 PGR
5 neoplasm MP:0002006 9.43 CDH1 ERBB2 MUC2 NKX2-1 PGR TP53
6 reproductive system MP:0005389 9.17 CDH1 ERBB2 MST1R NKX2-1 PGR TP53

Drugs & Therapeutics for Papillary Adenocarcinoma

Drugs for Papillary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 44)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
2
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
3
Everolimus Approved Phase 2 159351-69-6 6442177
4
Bevacizumab Approved, Investigational Phase 2 216974-75-3
5
Nivolumab Approved Phase 2 946414-94-4
6
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
7
Gemcitabine Approved Phase 2 95058-81-4 60750
8
Olaparib Approved Phase 1, Phase 2 763113-22-0 23725625
9
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
10
Maleic acid Experimental Phase 1, Phase 2 110-16-7 444266
11
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
12
Doxil Approved June 1999 Phase 2 31703
13
Atrasentan Investigational Phase 2 195733-43-8, 173937-91-2 159594
14 Immunoglobulins Phase 2
15 Immunoglobulin G Phase 2
16 Anti-Infective Agents Phase 2
17 Immunologic Factors Phase 2
18 Antibodies Phase 2
19 Immunosuppressive Agents Phase 2
20 Antifungal Agents Phase 2
21 Angiogenesis Modulating Agents Phase 2
22 Anti-Bacterial Agents Phase 2
23 Antibodies, Monoclonal Phase 2
24 Antibiotics, Antitubercular Phase 2
25 Mitogens Phase 2
26 Angiogenesis Inhibitors Phase 2
27 Endothelial Growth Factors Phase 2
28 Liver Extracts Phase 2
29 Estrogen Antagonists Phase 2
30 Steroid Synthesis Inhibitors Phase 2
31 Aromatase Inhibitors Phase 2
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
33 Hormones Phase 2
34 Estrogens Phase 2
35 Estrogen Receptor Antagonists Phase 2
36 Hormone Antagonists Phase 2
37 Antiviral Agents Phase 2
38 Antimetabolites Phase 2
39 Antimetabolites, Antineoplastic Phase 2
40 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
41 Protein Kinase Inhibitors Phase 1, Phase 2
42 taxane Phase 2
43 Topoisomerase Inhibitors Phase 2
44 Endothelin Receptor Antagonists Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
2 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
3 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
4 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Active, not recruiting NCT02283658 Phase 2 Everolimus;Letrozole
5 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
6 Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting NCT01116648 Phase 1, Phase 2 Cediranib Maleate;Olaparib
7 Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma Terminated NCT00653328 Phase 2 atrasentan hydrochloride;doxil
8 Research Study in Patients With Advanced Ovarian Epithelial Cancer Withdrawn NCT00053235

Search NIH Clinical Center for Papillary Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, papillary

Genetic Tests for Papillary Adenocarcinoma

Anatomical Context for Papillary Adenocarcinoma

MalaCards organs/tissues related to Papillary Adenocarcinoma:

41
Thyroid, Lung, Cervix, Ovary, Pancreas, Testis, Kidney

Publications for Papillary Adenocarcinoma

Articles related to Papillary Adenocarcinoma:

(show top 50) (show all 376)
# Title Authors Year
1
Papillary Adenocarcinoma in a Gastric Duplication Cyst. ( 29563742 )
2018
2
Endonasal endoscopic nasopharyngectomy for the treatment of nasopharyngeal papillary adenocarcinoma: Report of a rare case. ( 29287881 )
2018
3
Nasopharyngeal Papillary Adenocarcinoma as a Second Head and Neck Malignancy. ( 29923095 )
2018
4
Clinicopathologic Characteristics of Thyroid-like Low-grade Nasopharyngeal Papillary Adenocarcinoma: A Case Report. ( 29494399 )
2018
5
The So-Called Aggressive Digital Papillary Adenocarcinoma Is Epithelial-Myoepithelial Carcinoma. ( 29384814 )
2018
6
Pulmonary papillary adenocarcinoma with<i>Aspergillus versicolor</i>infection in a dog. ( 29234587 )
2018
7
Aggressive Digital Papillary Adenocarcinoma: Population-Based Analysis of Incidence, Demographics, Treatment, and Outcomes. ( 29578881 )
2018
8
Gene expression profiling in aggressive digital papillary adenocarcinoma sheds light on the architecture of a rare sweat gland carcinoma. ( 30472730 )
2018
9
Biphasic low-grade nasopharyngeal papillary adenocarcinoma: a case report and literature review. ( 30323715 )
2018
10
Thyroid-Like Low-Grade Nasopharyngeal Papillary Adenocarcinoma. ( 29995295 )
2018
11
Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach: low curative resection rate but favorable long-term outcomes after curative resection. ( 30039320 )
2018
12
Low-grade papillary adenocarcinoma of nasopharynx. Case report and review of the literature. ( 30075860 )
2018
13
Aggressive digital papillary adenocarcinoma: A clinicopathological study of 19 cases. ( 28495496 )
2017
14
Response to: Cutaneous papillary adenocarcinoma in situ. ( 28299799 )
2017
15
Endoscopic submucosal dissection for papillary adenocarcinoma of the stomach: is it really safe? ( 28271420 )
2017
16
Lymphovascular invasion and lymph node metastasis rates in papillary adenocarcinoma of the stomach: implications for endoscopic resection. ( 29280035 )
2017
17
Primary thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: A case report and literature review. ( 29381996 )
2017
18
Aggressive Digital Papillary Adenocarcinoma of the Hand Presenting as a Felon. ( 28421154 )
2017
19
Clinicopathological and molecular stability and methylation analyses of gastric papillary adenocarcinoma. ( 28830689 )
2017
20
Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with squamous differentiation: A novel histological finding. ( 28601658 )
2017
21
Primary papillary adenocarcinoma of the lung: Report of two cases. ( 28474664 )
2017
22
Masson's Tumor Masquerading as a Papillary Adenocarcinoma on Fine Needle Aspiration Cytology: A Case Report. ( 28272657 )
2017
23
Mohs Micrographic Surgery as a Digit-Sparing Treatment for Aggressive Digital Papillary Adenocarcinoma. ( 28291063 )
2017
24
Highly variable clinical feature and course of aggressive digital papillary adenocarcinoma. ( 29194742 )
2017
25
Aggressive digital papillary adenocarcinoma: treatment with Mohs micrographic surgery and an update of the literature. ( 28832985 )
2017
26
An Alpha Fetoprotein Producing Gastric Tumor with Yolk Sac, Hepatoid and Papillary Adenocarcinoma Components. ( 29207718 )
2017
27
Cutaneous papillary adenocarcinoma in situ. ( 28164358 )
2017
28
Cronkhite-Canada Syndrome with a Major Duodenal Papillary Adenocarcinoma. ( 28924129 )
2017
29
Nasopharyngeal papillary adenocarcinoma. ( 29236265 )
2017
30
Clinicopathological Features of Low-Grade Thyroid-Like Nasopharyngeal Papillary Adenocarcinoma. ( 27384157 )
2016
31
Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: A case report. ( 28105348 )
2016
32
Low-grade papillary adenocarcinoma of nasopharynx with expression of thyroid transcription factor-1: Case report and review of literature. ( 27721286 )
2016
33
A retrospective review of 11 cases of villoglandular papillary adenocarcinoma of the uterine cervix and a review of the literature. ( 26998142 )
2016
34
Low-grade nasopharyngeal papillary adenocarcinoma: a case report and review of the literature. ( 27274289 )
2016
35
Malignant transformation of alveolar adenoma to papillary adenocarcinoma: a case report. ( 27162700 )
2016
36
Aggressive papillary adenocarcinoma on atypical localization: A unique case report. ( 27428196 )
2016
37
Aggressive Digital Papillary Adenocarcinoma With Multiple Organ Metastases: A Case Report and Review of the Literature. ( 27870729 )
2016
38
Treatment of endolymphatic sac tumour (Papillary adenocarcinoma) of the temporal bone. ( 27330425 )
2016
39
Papillary adenocarcinoma with tentacular processes (with video). ( 27302875 )
2016
40
Villoglandular papillary adenocarcinoma: case report. ( 28293348 )
2016
41
Papillary adnexal neoplasm (Aggressive digital papillary adenocarcinoma) on the ankle of a 15 year old girl: case report and review of literature from a pediatric perspective. ( 27535353 )
2016
42
Role of Radiotherapy in Aggressive Digital Papillary Adenocarcinoma. ( 27098633 )
2016
43
Papillary adenocarcinoma of the renal pelvis with renal calculus: A rare case report. ( 27123287 )
2016
44
An unexpected digital papillary adenocarcinoma of the thumb. ( 27990456 )
2016
45
Metastatic Papillary Adenocarcinoma in a 22-Year-Old: Is Her History of Mayer-Rokitansky-KA1ster-Hauser Syndrome Causative or Incidental? ( 27987200 )
2016
46
Villoglandular papillary adenocarcinoma of the uterine cervix: A report of 4 cases and a review of the literature. ( 26870293 )
2016
47
Nasopharyngeal thyroid-like low-grade papillary adenocarcinoma. ( 29727129 )
2016
48
Aggressive Digital Papillary Adenocarcinoma: Case Report of a Positive Sentinel Lymph Node and Discussion of Utility of Sentinel Lymph Node Biopsy. ( 25954845 )
2015
49
Aggressive Digital Papillary Adenocarcinoma. ( 26576210 )
2015
50
&amp;quot;Apocrine Hidrocystoma and Cystadenoma&amp;quot;-like Tumor of the Digits or Toes: A Potential Diagnostic Pitfall of Digital Papillary Adenocarcinoma. ( 26523544 )
2015

Variations for Papillary Adenocarcinoma

Expression for Papillary Adenocarcinoma

Search GEO for disease gene expression data for Papillary Adenocarcinoma.

Pathways for Papillary Adenocarcinoma

GO Terms for Papillary Adenocarcinoma

Cellular components related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.8 MUC1 MUC16 MUC2

Biological processes related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.56 ERBB2 NKX2-1 TP53 VIM
2 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.16 MUC1 TP53
3 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.13 MUC1 MUC16 MUC2
4 O-glycan processing GO:0016266 8.8 MUC1 MUC16 MUC2

Molecular functions related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.46 MUC1 NKX2-1 PGR TP53
2 enzyme binding GO:0019899 9.26 MST1R NKX2-1 PGR TP53
3 identical protein binding GO:0042802 9.1 CDH1 CEACAM5 ERBB2 PGR TP53 VIM

Sources for Papillary Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....